CTRI/2018/11/016335尚未招募未知
A randomized, assessor-blind, two treatment, two-period, two-way crossover, bioequivalence study of recombinant human follicle stimulating hormone (r-hFSH) of Intas Pharmaceuticals Ltd. with Gonal-F, in pituitary down-regulated healthy female subjects
试验速览
- 阶段
- 未知
- 状态
- 尚未招募
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1) Healthy, adult, pre-menopausal (FSH level less than or equal to 25 mIU/mL) females between greater than or equal to 18 and less than or equal to 45 years of age (both inclusive) and having regular menstrual cycles of 25â??34 days before initiation of Leuprorelin acetate.
- •2) Body mass index (BMI) within the range of 18- 30 kg per meter square (Both inclusive)
- •3) Females who are sexually active and with male partners must be willing to use one of the following acceptable contraceptive methods throughout the study and for 30 days after the last study drug administration (Common locally used acceptable contraceptive methods)
- •a. Intra-uterine contraceptive device (without hormone release system).
- •b. Double barrier contraceptive measure.
- •c. Sterile male partner (vasectomized since at least 6 months)
- •d. Females who have undergone tubal ligation.
- •4) Subjects should understand the requirements of the protocol, willing to follow the protocol-specified requirements as explained during informed consent and should be capable of providing written informed consent.
排除标准
- •1) History of clinically significant illness and/or surgery within 4 weeks prior to dosing with leuprorelin acetate.
- •2) Any History of clinically significant history of neurological, endocrinal, cardiovascular (thrombo-embolic disorders), pulmonary (asthma), hematological (porphyria), immunologic, psychiatric, gastrointestinal, renal, hepatic, and metabolic disease.
- •3) Thyroid function tests outside the normal reference limits of the laboratory.
- •4) History of clinically significant ovarian, uterine or mammary disease e.g. Polycystic ovary syndrome, ovarian hyperstimulation syndrome, endometriosis class 3 or 4, submucosal myoma uteri, Ovarian diseases.
- •5) History of undiagnosed abnormal vaginal bleeding and having irregular menstrual cycles.
- •6) Abnormal Papanicolaou smear within 12 months prior to administration of leuprorelin acetate.
- •7) Any clinically significant abnormality or abnormal laboratory test results found during medical screening or positive test for hepatitis B (HBsAg, HBcIgM), hepatitis C, or HIV antibody (I & II) found during medical screening.
- •8) Any clinically significant abnormal abdominal & pelvic ultrasound scan results found during medical screening.
- •9) Positive urine drug screen at baseline.
- •10) History of allergic reactions or hypersensitivity to leuprorelin acetate, r-hFSH (follitropin alfa), or similar related drugs.
- •11) Any reason which, in the opinion of the Investigator, would prevent the subject from participating in the study.
- •12) Clinically significant electrocardiogram (ECG) abnormalities or vital sign abnormalities (systolic blood pressure less than 90 or more than 140 mmHg, diastolic blood pressure less than 60 or more than 90 mmHg, or pulse rate less than 50 or more than 100 bpm) at screening.
- •13) Donation of blood (1 unit or 350mL) or receipt of an investigational product, or participation in a drug research study within 6 months prior to receiving the first dose of study medicine.
- •14) Subjects with history of use of any Chinese hamster ovary (CHO) cell-derived product e.g. Inj FSH, Inj Bevacizumab, etc.
- •15) Use of medication other than topical products with significant systemic absorption
- •16) Pregnant or nursing (lactating) subject.
- •17) Smokers (tobacco users) or those who have stopped smoking within last 6 months prior to start of the study.
- •18) History of malignant diseases
研究者
相似试验
进行中（未招募）
1 期
A randomized, double-blind, placebo-controlled, parallel group trial of HMR1766 assessing the efficacy and safety of 3 doses of HMR1766 (25, 100, 200 mg OD) versus placebo with cilostazol, 100 mg BID as a calibrator, administered for 26 weeks in patients with Peripheral Arterial Disease (PAD) Fontaine stage II. - ACCELAPeripheral Arterial Disease (PAD) Fontaine stage II (intermittent claudication)MedDRA version: 8.1Level: LLTClassification code 10022562Term: Intermittent claudicationEUCTR2006-004275-35-FRsanofi-aventis recherche & développement550
进行中（未招募）
不适用
A study to determine the appropriate dose(s) of Dupilumab (REGN668)in adult patients with moderate to severe atopic dermatitis (eczema)Atopic dermatitsMedDRA version: 16.1Level: LLTClassification code 10003639Term: Atopic dermatitisSystem Organ Class: 100000004858EUCTR2012-003651-11-PLRegeneron Pharmaceuticals, Inc.240
进行中（未招募）
不适用
A randomized, double-blind, placebo-controlled, parallel group trial of HMR1766 assessing the efficacy and safety of 3 doses of HMR1766 (25, 100, 200 mg OD) versus placebo with cilostazol, 100 mg BID as a calibrator, administered for 26 weeks in patients with Peripheral Arterial Disease (PAD) Fontaine stage II. - ACCELAPeripheral Arterial Disease (PAD) Fontaine stage II (intermittent claudication)MedDRA version: 8.1Level: LLTClassification code 10022562Term: Intermittent claudicationEUCTR2006-004275-35-ATsanofi-aventis recherche & développement550
进行中（未招募）
1 期
Efficacy and safety of dexketoprofen trometamol and tramadol hydrochloride combination on moderate to severe acute pain in patients with acute low back paiow back painMedDRA version: 21.0Level: LLTClassification code 10024891Term: Low back painSystem Organ Class: 100000004859EUCTR2019-003656-37-ESMenarini International Operations Luxembourg SA538
进行中（未招募）
不适用
A randomized, double-blind, placebo-controlled, parallel group study of the safety and reduction of signs and symptoms during treatment with MRA versus placebo, in combination with traditional DMARD therapy in patients with moderate to severe active rheumatoid arthritis and an inadequate response to current DMARD therapy.Rheumatoid ArthritisEUCTR2004-005210-37-DEF. Hoffmann La-Roche AG1,200